Jose Mauricio Mota

Radiorecurrent prostate cancer. Two salvage options. Same 10-year survival. But salvage focal therapy had lower complication vs radical surgery. Outcomes equal. @JAMAOnc @Tilki_De @DrShariat @OncoAlert @APCCC_Lugano

9 years. Still responding. CheckMate 214 final analysis: 31% of nivo+ipi patients alive at 9 years. Nearly half still in response at 96 months. What does durable remission mean for your patients? @Annals_Oncology @myESMO @DrChoueiri @AlbigesL @HHammersMD @ERPlimackMD @tompowles1 @cdanicas @ViktorGruenwald @brian_rini @motzermd @OncoAlert

🚨 Can we delay ADT in oligometastatic HSPC… without compromising control? The phase 2 BULLSEYE trial answers this with radioligand therapy. 👥 Study population: Biochemically recurrent, PSMA+ oligometastatic HSPC - ≤5 mets, PSA DT <6 months - Not candidates for surgery/SBRT - ADT-naïve ⚡ Trial design: 🟣 ¹⁷⁷Lu-PSMA-617 (2–4 cycles) vs ⚪ Deferred ADT (active monitoring) 📊 Key results: 🔥 Progression at 30 weeks: 7% vs 93% 🔥 Median PFS: 25 vs 5 months 🔥 HR 0.07 (p<0.0001) 📉 PSA responses: - ≥50% decline: 83% vs 0% - ≥90% decline: 52% - Complete biochemical response: 24% 🛡️ Safety: Mostly grade 1–2 - Grade 3 AEs: rare (dry eyes 3%, lymphopenia 10%) - No grade 4 toxicity or treatment-related deaths 💡 Takeaway: Radioligand therapy can dramatically delay progression and postpone ADT in selected oligometastatic HSPC patients. But: Small phase 2 + crossover design → not practice-changing yet 👉 A glimpse of a future where we treat early metastatic disease without hormones? 🔖 Save this for clinic discussions 📖 Full paper in comment ⬇️ #OncoTwitter #MedTwitter #ProstateCancer #NuclearMedicine @OncoAlert @myesmo @esmo_open @asc

Prof Hugosson: Göteborg trial with 30 year outcomes! NND falls to -6-, with greatest benefit for men 50-59 at randomization. Despite no image guidance, high overdx, and suboptimal tx. Best evidence we have re: the evidence for #prostatecancer screening. Get tested! #eau26 @uroweb

📹 WATCH: Dr Jose Mauricio Mota @motajmsc of @Icesp_ talks about the phase 2 Daro-PET testing darolutamide to boost PSMA PET signal in high-risk localized #ProstateCancer, guiding improved imaging interpretation. #GU26 hubs.li/Q0450_9Q0

PCWG4 out in @JCO_ASCO today concurrent with #GU26. Lots of key updates here for advanced #prostatecancer management! ascopubs.org/doi/10.1200/JC…

@urotoday @Icesp_ @zklaassen_md @GACancerCenter @ASCO @jessicamvasco_

Daro-PET: A phase 2 trial of darolutamide to enhance PSMA expression in patients with localized #ProstateCancer. Presentation by @motajmsc @Icesp_. #GU26 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4sie08Z @ASCO

@zklaassen_md @urotoday @jessicamvasco_

Daro-PET: Ph 2 trial of Daro to enhance PSMA expression in localized PCa #GU26 @urotoday @motajmsc ♦️n=16, BL PSMA PET --> 7 d DARO --> 2nd PSMA PET ♦️n=3 (18.8%) met prim endpoint (SUVmax ≥20% increase) -- range SUVmax ⬆️ 36.5–62% ♦️n=3 had 2 prostate uptake foci, w/ heterogeneous changes in PSMA uptake after Daro

@urotoday @Icesp_ @zklaassen_md @GACancerCenter @ASCO @Institutodor @Icesp_

@zklaassen_md @urotoday @Institutodor @Icesp_

2025 FDA drug approvals nature.com/articles/d4157… The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency. Read about the trends and highlights, and see the full list of approved therapeutics in our annual round up

@LiangChengMD @bcarneiro7 @weldeiry Congrats Bene @bcarneiro7

What’s new in the space of antibody-drug conjugates (ADCs) for metastatic castration-resistant prostate cancer (mCRPC)? Congratulations to Bene @bcarneiro7,  Claire, and colleagues @weldeiry for publishing this outstanding state-of-the-art review in NPJ Precision Oncology @Nature_NPJ  PMID:41238753  DOI: 10.1038/s41698-025-01131-0 ADCs represent a rapidly evolving class of biotherapeutics, combining the tumor-targeting specificity of monoclonal antibodies with the cytotoxic potency of small-molecule payloads. This comprehensive review outlines advances in cytotoxic payload and linker chemistry, and synthesizes emerging evidence on membrane antigens overexpressed in prostate cancer - including PSMA, B7-H3, STEAP1, TROP2, CD46, TF, DLL3, SLC44A4, HER2/HER3, Nectin-4, 5T4, KAAG1, ASCT2, LYPD3, Tag-72, TM4SF1, CDH3, ROR1, and PSCA. Although no ADC has yet been approved for prostate cancer due to challenges related to safety, specificity, and therapeutic window, progress in antigen selection, linker design, and next-generation payloads is accelerating development. These innovations hold significant promise to reshape the treatment paradigm for mCRPC and improve patient outcomes.

How much do urological cancers affect the working-age population worldwide? A new analysis in Annals of Surgical Oncology looked at prostate, kidney, bladder, and testicular cancers in people aged 15–64 from 1990–2021, with projections to 2050.

⚡️ Hyper-progression with Nivolumab + Ipilimumab in RMC Phase II data in renal medullary carcinoma show rapid progression in all treated patients, with half meeting criteria for hyper-progression. Single-cell analyses indicate an IFN-γ–driven “myeloid mimicry” program in SMARCB1-deficient tumors. #KidneyCancer #Immunotherapy #GUOncology @PavlosMsaouel @NatureComms nature.com/articles/s4146…

Bladder cancer #ESMO25 in 1 slide. #goosebumps #newSOCnow #micdrop #standingovation Neoadjuvant EVP = New SOC MIBC Cis-ineligible!

The results of #POTOMAC trial are out in @TheLancet simultaneously released with #ESMO25 presentation @myESMO Happy to share our thoughts on this also out in the accompanying editorial. @SanRaffaeleMI @MyUniSR Front-line durvalumab and BCG in the treatment of non-muscle-invasive bladder cancer - The Lancet thelancet.com/journals/lance…

The CRASH-2 trial proved tranexamic acid helps in trauma. But does it help in radical cystectomy? The answer is no. Our meta-analysis (1,736 pts) published this month in the @CuaJournal explains why. Grateful to my amazing co-authors

@juanosoriomd @MSKCancerCenter Congrats Juan. Warm regards from 🇧🇷!

Excited to launch my independent lab at @MSKCancerCenter’s new Immuno-Oncology Program! 🎉 We’ll study antibody-mediated immunity & myeloid biology to fuel next-gen cancer immunotherapies. mskcc.org/research-areas…